Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation

Abstract Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy. Objective: To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy. Methods: The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased. Results: A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation. Conclusion: In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5).

Saved in:
Bibliographic Details
Main Authors: Baptista,Ana, Magalhães,Pedro, Leão,Sílvia, Carvalho,Sofia, Mateus,Pedro, Moreira,Ilídio
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Cardiologia - SBC 2015
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015002100139
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0066-782X2015002100139
record_format ojs
spelling oai:scielo:S0066-782X20150021001392016-06-13Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel MutationBaptista,AnaMagalhães,PedroLeão,SílviaCarvalho,SofiaMateus,PedroMoreira,Ilídio Fabry disease / complications Hypertrophy, left ventricular Alpha-Galactosidase / genetics Abstract Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy. Objective: To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy. Methods: The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased. Results: A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation. Conclusion: In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5).info:eu-repo/semantics/openAccessSociedade Brasileira de Cardiologia - SBCArquivos Brasileiros de Cardiologia v.105 n.2 20152015-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015002100139en10.5935/abc.20150090
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Baptista,Ana
Magalhães,Pedro
Leão,Sílvia
Carvalho,Sofia
Mateus,Pedro
Moreira,Ilídio
spellingShingle Baptista,Ana
Magalhães,Pedro
Leão,Sílvia
Carvalho,Sofia
Mateus,Pedro
Moreira,Ilídio
Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
author_facet Baptista,Ana
Magalhães,Pedro
Leão,Sílvia
Carvalho,Sofia
Mateus,Pedro
Moreira,Ilídio
author_sort Baptista,Ana
title Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
title_short Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
title_full Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
title_fullStr Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
title_full_unstemmed Screening for Fabry Disease in Left Ventricular Hypertrophy: Documentation of a Novel Mutation
title_sort screening for fabry disease in left ventricular hypertrophy: documentation of a novel mutation
description Abstract Background: Fabry disease is a lysosomal storage disease caused by enzyme α-galactosidase A deficiency as a result of mutations in the GLA gene. Cardiac involvement is characterized by progressive left ventricular hypertrophy. Objective: To estimate the prevalence of Fabry disease in a population with left ventricular hypertrophy. Methods: The patients were assessed for the presence of left ventricular hypertrophy defined as a left ventricular mass index ≥ 96 g/m2 for women or ≥ 116 g/m2 for men. Severe aortic stenosis and arterial hypertension with mild left ventricular hypertrophy were exclusion criteria. All patients included were assessed for enzyme α-galactosidase A activity using dry spot testing. Genetic study was performed whenever the enzyme activity was decreased. Results: A total of 47 patients with a mean left ventricular mass index of 141.1 g/m2 (± 28.5; 99.2 to 228.5 g/m2] were included. Most of the patients were females (51.1%). Nine (19.1%) showed decreased α-galactosidase A activity, but only one positive genetic test − [GLA] c.785G>T; p.W262L (exon 5), a mutation not previously described in the literature. This clinical investigation was able to establish the association between the mutation and the clinical presentation. Conclusion: In a population of patients with left ventricular hypertrophy, we documented a Fabry disease prevalence of 2.1%. This novel case was defined in the sequence of a mutation of unknown meaning in the GLA gene with further pathogenicity study. Thus, this study permitted the definition of a novel causal mutation for Fabry disease - [GLA] c.785G>T; p.W262L (exon 5).
publisher Sociedade Brasileira de Cardiologia - SBC
publishDate 2015
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2015002100139
work_keys_str_mv AT baptistaana screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation
AT magalhaespedro screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation
AT leaosilvia screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation
AT carvalhosofia screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation
AT mateuspedro screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation
AT moreirailidio screeningforfabrydiseaseinleftventricularhypertrophydocumentationofanovelmutation
_version_ 1756381981422125056